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Introduction
The “Hallmarks of Cancer,” proposed by Hanahan and Weinburg in 2001 and updated in
2011, logically define how a normal cell progresses to a tumorigenic state within a complex
neoplastic environment [1]. These hallmark capabilities have given us remarkable insight into
the multistep changes that occur within the tissue microenvironment during cancer develop-
ment. However, it has become well established that host-associated microbial communities,
termed microbiota, also play integral roles in modulating various aspects of host physiology.
This includes host processes such as cellular metabolism and immune function that become
highly dysregulated during carcinogenesis. Perturbations to the microbiota also disrupt these
homeostatic processes, promoting the development of numerous diseases including inflamma-
tory bowel diseases (IBD) and colorectal cancer (CRC). Helicobacter pylori served as the initial
link between bacteria and cancer, when it was discovered that infection predisposed humans
to gastric cancer [2]. More recently, fast and inexpensive next-generation sequencing methods
combined with research initiatives to support multi-investigator research teams (for example,
the National Institutes of Health (NIH)-funded Human Microbiome Project) have revolution-
ized our understanding of the microbiota and human disease. In parallel, animal models have
demonstrated a causal relationship between particular microbes and cancer development
through fecal transplants from cancer-bearing mice or inoculation of cancer-associated
microbes into formerly germ-free mice. Together, these studies have shown that our resident
microbes likely influence the initiation and progression of tumorigenesis by modulating most,
if not all, established host factors that comprise the hallmarks of cancer. Further knowledge
defining how the microbiota modulates host physiology and disease pathogenesis, particularly
in the context of cancer, will provide a framework for the holobiont concept of cancer develop-
ment and enable the identification of novel microbial targets for preventative and therapeutic
strategies. This review will explore how specific members of the microbiota, summarized in
Fig 1 and Table 1, influence the hallmarks of cancer.
How does the microbiota influence cellular proliferation and host cellular
energetics?
Normal tissues tightly regulate growth-promoting and death-inducing signals to maintain
homeostatic cell densities, tissue architecture, and function. Dysregulation of these signaling
pathways can lead to sustained cellular proliferation. The intercellular adhesion molecule, E-
cadherin, is a common target engaged by intestinal bacteria that promotes epithelial prolifera-
tion by activating the Wnt/ß-catenin pathway. For example, enterotoxigenic Bacteroides fragi-
lis (ETBF), resident among the microbiota of some individuals, secretes B. fragilis toxin (BFT)
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that promotes cleavage of E-cadherin [3]. This enables the nuclear translocation of ß-catenin,
subsequent transcription of proto-oncogene c-Myc, and colonic epithelial hyperplasia [3].
Through a similar mechanism, Fusobacterium nucleatum enhances epithelial proliferation
through engagement of its adhesin FadA with E-cadherin [4]. Neutralizing FadA abrogated
the tumor-promoting activities of F. nucleatum in a murine xenograft cancer model [4], dem-
onstrating the potential of targeting bacterial interactions with E-cadherin as a novel strategy
in mitigating cancer progression. Taken together, these studies demonstrate that the micro-
biota can be a source of activating signals for aberrant epithelial proliferation as an initiating
step in cancer development.
Cellular senescence—when cells cease to divide—is often considered a barrier for prolifera-
tion. However, senescent cells secrete growth factors that enable tumor growth, and intestinal
bacteria may induce this pathway to malignancy. Colibactin-producing (pks+) Escherichia coli
induce a senescence-associated secretory phenotype (SASP) in which senescent cells secrete
growth factors that stimulate epithelial proliferation and enhance tumor growth [5]. Thus,
microbial-induced cellular senescence and bystander proliferation provide additional mecha-
nisms by which malignancy can arise from host–microbial interactions.
Fig 1. Microbial-derived signals modulate numerous hallmarks of cancer through diverse mechanisms.
https://doi.org/10.1371/journal.ppat.1006480.g001
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Perturbations to the local metabolic environment can also favor or inhibit sustained cancer
cell proliferation and tumorigenesis. For example, the microbial metabolome has long been
established as a modulator of host cellular metabolism. Short-chain fatty acids such as butyrate
are generated through microbial fermentation of dietary fibers and are a preferred primary
energy source for colonocytes. In contrast, cancer cells preferentially utilize glucose as a carbon
source through glycolysis—a phenomenon known as the Warburg effect. Butyrate not only
exerts an anticancer effect by starving cancer cells, but impaired butyrate metabolism increases
intracellular concentrations of butyrate, which acts as a histone deacetylase inhibitor and pro-
motes apoptosis and inhibition of cellular proliferation through epigenetic modifications [6].
Given the complexity of the microbial metabolome, it will be important to broaden our inves-
tigation beyond individual metabolites and consider the impact of the metabolome as a whole
on cellular energetics and other hallmarks of cancer.
How does the microbiota shape the local tumor microenvironment?
The microbiota influences cancer development by modulating the local tumor microenviron-
ment through its effects on tissue remodeling and mucosal immunity. Angiogenesis, one
aspect of tissue remodeling that occurs during tumorigenesis, enables adequate blood flow,
Table 1. Members of the intestinal microbiota associated with cancer development and resistance.
Intestinal bacteria Bacterial
mechanism
Hallmark affected Mouse models References
enterotoxigenic Bacteroides fragilis
(ETBF)
B. fragilis toxin
(BFT)
sustaining
proliferative signaling
WT mice [3]
genome instability and
mutations
ApcMin/+ [21]
unknown
mechanism
tumor-promoting
inflammation
ApcMin/+ [10]
Fusobacterium nucleatum FadA adhesin sustaining
proliferative signaling
xenograft model [4]
Fap2 adhesin avoiding immune destruction ApcMin/+ [14]
[13]
pks+
Escherichia coli
colibactin genome instability and
mutations
in vitro cellular assays [19]
AOM/Il10-/- [20]
sustaining
proliferative signaling
AOM/DSS
xenograft model
[5]
Enterococcus faecalis unknown
mechanism
genome instability and
mutations
allograft model [22]
Alistipes spp. unknown
mechanism
tumor-promoting
inflammation
Il10-/- Lcn2-/- [12]
Bifidobacterium spp. unknown
mechanism
inhibits avoiding immune
destruction
subcutaneous B16.SIY melanoma [15]
Bacteroides thetaiotamicron and B.
fragilis
unknown
mechanism
inhibits avoiding immune
destruction
MCA205 sarcoma, Ret melanoma, and MC38
CRC xenograft
[16]
Abbreviations: AOM, azoxymethane; Apc, adenomatosis polyposis coli; CRC, colorectal cancer; DSS, dextran sodium sulfate; Il10, interleukin 10; Lcn2,
lipocalin2; Min, multiple intestinal neoplasia
https://doi.org/10.1371/journal.ppat.1006480.t001
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which is integral for tumor persistence and proliferation. Although direct links between
endogenous bacteria and tumor-associated angiogenesis have not been reported, the micro-
biota is required for normal development of the vasculature within the intestines [7]. More-
over, in the context of infection, microbial products such as lipopolysaccharide engage with
Toll-like receptors to promote angiogenesis, an effect that is augmented by damage-associated
molecular patterns that may also be present within the tumor microenvironment [8]. Further
studies will determine whether specific microbes influence angiogenesis and tumor-associated
remodeling of the vasculature.
The close proximity of the microbiota and mucosal immune system also provides the
potential for endogenous bacteria to impact the tumor microenvironment by stimulating a
variety of protumorigenic immune responses. T-helper-17 (Th17) immunity is generally pro-
tumorigenic, associated with worse prognosis in CRC, and driven by microbes and microbial
products [9]. Colonization of tumor-susceptible adenomatosis polyposis coli–multiple intesti-
nal neoplasia (ApcMin/+) mice with ETBF enhances Th17-driven inflammation and colonic
tumor development [10] [11]. Blocking the interleukin-(IL)-17 signaling axis reduces down-
stream signal transducer and activator of transcription factor 3 (STAT3) signaling in tumor
and nontumor cells, thus preventing inflammation and tumorigenesis [10] [11]. Similarly, the
carcinogenic potential of the intestinal commensal Alistipes is associated with enhanced IL-6
production, STAT3 activation, epithelial hyperplasia, and epithelial barrier dysfunction [12].
Thus, specific members of the microbiota stimulate Th17-driven inflammation and aid in
establishing a tumor-permissive inflammatory environment.
While Th17 immune responses promote tumor development, others involving cytotoxic
immune cells are essential for identifying and destroying precancerous and malignant cells. F.
nucleatum dampens this arm of cancer immunity through 2 distinct mechanisms to enable
tumor progression and persistence. F. nucleatum utilizes its Fap2 adhesion to silence the
tumor-killing capabilities of cytotoxic immune cells through direct interaction with the
immune inhibitory receptor T-cell immunoreceptor with immunoglobulin and immunore-
ceptor tyrosine-based inhibitory motif domains (TIGIT) [13]. F. nucleatum abundance is also
correlated in clinical and animal studies with an enrichment of myeloid-derived suppressor
cells and tumor-associated macrophages, both of which inhibit antitumor T-cell responses
[14].
While some resident intestinal bacteria inhibit antitumor immunity, others stimulate anti-
tumor immunity and potentiate cancer immunotherapy. Bifidobacterium augments dendritic
cell function and subsequent tumor-killing capabilities of cytotoxic T cells, which correspond
with reduced growth of subcutaneous melanoma xenograft models in mice [15]. Bifidobacter-
ium administration in combination with the established anticancer immunotherapeutic pro-
grammed death-ligand 1 (PD-L1) blockade nearly abolished tumor growth [15]. Similarly,
Bacteroides thetaiotamicron and nontoxigenic B. fragilis improve the efficacy of an anti–cyto-
toxic T-lymphocyte-associated protein 4 (CTLA4) immunotherapeutic tested in 3 cancer
xenograft mouse models. This is achieved by augmenting antitumor cytotoxic T-cell immunity
and is associated with T-cell responses specific for B. thetaiotamicron or B. fragilis [16]. While
B. fragilis polysaccharides can enhance antitumor immunity [16], the specific B. fragilis poly-
saccharide A (PSA) promotes an anti-inflammatory state in the intestine by fine-tuning the
balance of effector and regulatory T cells [17] [18]. However, it remains unclear whether the
anti-inflammatory effects of PSA impact cancer development and the efficacy of cancer immu-
notherapies. Together, these findings introduce the exciting prospect of manipulating the
microbiota as a means of not only modulating cancer-associated tissue remodeling and immu-
nity but also enhancing the efficacy of established anticancer therapies.
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Does the microbiota promote genome instability and mutations?
The breakdown of genome maintenance within the host, whether through DNA damage accu-
mulation or failure to properly segregate chromosomes, allows premalignant and malignant
cells to both retain and accelerate the rate of mutations. Several gut microbes are a potential
source of DNA mutagens. In vitro studies first demonstrated that pks+ E. coli induce DNA
double-strand breaks, aneuploidy, cell-cycle arrest, and improper cellular division [19]. Multi-
ple animal models of CRC have demonstrated that pks+ E. coli promote DNA damage in vivo,
yet inflammation remains unaffected and unlikely to be a driving force behind this damage
[20] [5]. In contrast, other resident microbes can induce DNA damage by promoting inflam-
mation and a pro-oxidant microenvironment. ETBF induces colonic epithelial expression of
spermine oxidase (SMO), an enzyme that generates the DNA-damaging agent peroxide. Inhi-
bition of SMO prevents ETBF-induced DNA damage, which corresponds with a decrease in
ETBF-induced inflammation and tumorigenesis [21]. Enterococcus faecalis infected macro-
phages promote DNA double-strand breaks, aneuploidy, and chromosomal instability in
murine colonic epithelial cells, which, once transformed, initiate tumor formation in a murine
allograft model [22]. The ability of microbes to both directly and indirectly cause DNA damage
and genomic instability make the microbiome both a potential risk factor and therapeutic
target.
Conclusions
The densest populations of endogenous microbes are found within the intestines and are in
close proximity to the epithelium and underlying mucosal immune system. As a result, the ear-
liest observations linking the microbiota with the hallmarks of cancer have primarily focused
on gastric cancers and CRC. Nonetheless, more recent studies have also implicated the micro-
biota in cancers at distal sites as a potential predictor of successful response to cancer therapy
and as a means to augment the efficacy of existing anticancer therapeutics. Furthermore, the
well-established link between several viruses and human cancers (i.e., Human papillomavirus
and cervical, genital, anal, and oral cancers; Epstein-Barr virus and lymphomas; hepatitis C
virus and hepatocellular carcinoma; Kaposi’s sarcoma–associated herpesvirus and Kaposi’s
sarcoma) provides a strong rationale to investigate the role of nonbacterial members of the
microbiota (virus, fungi, and archaea) in modulating the hallmark capabilities and cancer
development. Finally, the cancer microenvironment itself can enhance the procarcinogenic
activities of the microbiota [23], which further demonstrates the importance of the crosstalk
between host and microbe in modulating cancer progression. In summary, because of the
extensive capacity of the microbiota to influence many hallmarks of cancer, treatment for a
variety of cancers may soon involve personalized medicine targeting the microbiota.
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